Nebula Research & Development LLC Acquires New Position in Bristol-Myers Squibb (NYSE:BMY)

Nebula Research & Development LLC purchased a new position in Bristol-Myers Squibb (NYSE:BMY - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 12,527 shares of the biopharmaceutical company's stock, valued at approximately $709,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Transce3nd LLC bought a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $28,000. Fairway Wealth LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $28,000. Comprehensive Financial Planning Inc. PA purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $34,000. Westend Capital Management LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth $38,000. Finally, Tacita Capital Inc purchased a new position in Bristol-Myers Squibb during the 4th quarter worth $39,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Price Performance

NYSE BMY traded down $0.67 during trading hours on Thursday, reaching $49.53. The company's stock had a trading volume of 17,161,789 shares, compared to its average volume of 12,973,691. The firm has a market capitalization of $100.79 billion, a price-to-earnings ratio of -11.21, a P/E/G ratio of 2.07 and a beta of 0.41. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33. The company's 50-day moving average is $55.99 and its two-hundred day moving average is $56.41. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same quarter last year, the company earned ($4.40) EPS. On average, equities analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.01%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is presently 92.88%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on BMY shares. Jefferies Financial Group decreased their price target on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Cantor Fitzgerald reiterated a "neutral" rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Finally, Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $58.00.

Insider Buying and Selling

In other news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction dated Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.